

|  |   |
|--|---|
| <b>Clinical Policy Title:</b>              | erenumab-aooe, atogepant                |
| <b>Policy Number:</b>                      | RxA.587                                 |
| <b>Drug(s) Applied:</b>                    | Aimovig®, Qulipta™                      |
| <b>Original Policy Date:</b>               | 03/06/2020                              |
| <b>Last Review Date:</b>                   | 12/11/2025                              |
| <b>Line of Business Policy Applies to:</b> | All lines of business (except Medicare) |

## Criteria

### I. Initial Approval Criteria

#### A. Migraine Prophylaxis (must meet all):

1. Diagnosis of the following (a or b):
  - a. Episodic migraine: 4 to 14 migraine days per month;
  - b. Chronic migraine: more than 15 migraine days per month for  $\geq 3$  months;
2. Documentation of a trial of at least 2 months of two (2) of the following preventative therapies from different mechanisms of action, unless contraindicated or adverse effects are experienced:
  - a. Candesartan;
  - b. Antiepileptics: divalproex sodium, valproic acid, topiramate;
  - c. Beta-blockers: atenolol, metoprolol, nadolol, propranolol, timolol;
  - d. Antidepressants: amitriptyline, duloxetine, nortriptyline, venlafaxine;
3. For members currently treated with Botox for migraine (a, b, and c):
  - a. Diagnosis of chronic migraine;
  - b. Member has tried a minimum of 2 quarterly injections (6 months) of Botox;
  - c. Member has experienced and maintained a positive response;
4. Medication is not prescribed in combination with other CGRP inhibitors used for migraine prophylaxis\*.

\*Medication may be prescribed concurrently with other CGRP inhibitors used for acute migraine treatment.

#### All lines of Business (except Medicare)

**CGRP monotherapy initial approval duration:** 12 months

**CGRP and Botox dual therapy initial approval duration:** 3 months

### II. Continued Therapy Approval

#### A. Migraine Prophylaxis (must meet all):

1. Member is currently receiving medication that has been authorized by RxAdvance or the member has met initial approval criteria;
2. Members treated with Aimovig or Qulipta AND Botox for chronic migraine prophylaxis have achieved > 50% reduction in the frequency of days with headache or migraine;
3. Medication is not prescribed in combination with other CGRP inhibitors used for migraine prophylaxis\*.

\*Medication may be prescribed concurrently with other CGRP inhibitors used for acute migraine treatment.

#### Approval Duration

**All Lines of Business (except Medicare):** 12 months

**References**

1. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. *Headache*. 2024. Available at: <https://headachejournal.onlinelibrary.wiley.com/doi/full/10.1111/head.14692>. Accessed August 12, 2024.

| Review/Revision History   | Review/Revision Date | P&T Approval Date |
|---|----------------------|-------------------|
| Policy established.   | 02/25/2020           | 03/06/2020        |
| <p>Policy was reviewed.</p> <ol style="list-style-type: none"> <li>1. Clinical Policy Title Table was updated.</li> <li>2. Drug(s) Applied was updated.</li> <li>3. Line of Business Policy Applies to was update to all lines of business.</li> <li>4. Dosage forms were updated.</li> <li>5. APPENDIX A: Abbreviation/Acronym Key was updated to include SC.</li> <li>6. APPENDIX B: Therapeutic Alternatives verbiage was updated to “Below are suggested therapeutic alternatives based on clinical guidance ...”</li> <li>7. APPENDIX C was updated include detailed contraindications.</li> <li>8. Continued Therapy criteria II.A.1 was rephrased to "Currently receiving medication that has been authorized by RxAdvance..."</li> <li>9. Initial Approval criteria: Medicaid approval duration was updated to 3 months.</li> <li>10. Continued Approval criteria: Medicaid approval duration was updated to 6 months.</li> </ol> <p>References were updated.</p> | 09/28/2020           | 12/07/2020        |
| <p>Policy was reviewed:</p> <ol style="list-style-type: none"> <li>1. Statement about provider sample “The provision of provider samples does not guarantee coverage...” was added to Clinical Policy.</li> <li>2. Initial approval criteria I.A was updated to remove “Prescribed by.....pain specialist”.</li> <li>3. Initial Approval Criteria I.A.7.a, and Continued Therapy Criteria II.A.4.a was updated to remove,“ 70 mg (1 injection) once monthly”.</li> <li>4. Initial Approval Criteria I.A.7.b, and Continued Therapy Criteria II.A.4.b was updated to remove “if medical justification is provided”.</li> <li>5. Continued Therapy Approval II.A.1 was</li> </ol>   | 10/12/2021           | 12/07/2021        |

|   |            |            |
|---|------------|------------|
| <p>rephrased to "Member is currently receiving medication that has been authorized by RxAdvance...".</p> <p>Appendix B Therapeutic Alternative table was updated to include dosing regimen and maximum dose for divalproex (Depakote®), topiramate (Topamax®), propranolol (Inderal®), metoprolol (Lopressor®), timolol, amitriptyline (Elavil®), venlafaxine (Effexor®).</p> <p>7. Statement about drug listing format in Appendix B is updated to "Therapeutic alternatives are listed as generic (Brand name®) when the drug is available by both generic and brand, Brand name® when the drug is available by brand only and generic name when the drug is available by generic only".</p> <p>6. References were reviewed and updated.</p>  |            |            |
| <p>Policy was reviewed:</p> <ol style="list-style-type: none"> <li>1. Appendix B, Maximum Dose, metoprolol (Lopressor®): Updated maximum dose information from 400 mg/day to 450 mg/day.</li> <li>2. Disclaimer about contraindications "Contraindications listed reflect statements made in the manufacturer's package insert..." was added to Appendix C.</li> <li>3. References were reviewed and updated.</li> </ol>  | 08/30/2022 | 10/19/2022 |
| <p>Policy was reviewed:</p> <ol style="list-style-type: none"> <li>1. Clinical Policy Title, Drugs applied, Background, Dosing Information, Dosage forms and Appendix C: Contraindications Updated to include information regarding new drug fremanezumab-vfrm (Ajovy®) and atogepant (Qulipta™).</li> <li>2. Clinical Policy Title, Lines of Business Policy Applies to: Updated from All line of Business to All lines of business (except Medicare).</li> <li>3. Initial Approval Criteria, I.A.1: Updated diagnosis criteria from Diagnosis of episodic or chronic migraine to Diagnosis of the following (must meet a or b):             <ol style="list-style-type: none"> <li>a. Episodic migraine: between 4 to 14 migraine days per month;</li> <li>b. Chronic migraine: more than 15 headache days per month for ≥ 3 months.</li> </ol> </li> <li>4. Initial Approval Criteria, I.A.2: Updated to remove prior criteria pertaining to indication Migraine Prophylaxis, "Member</li> </ol> | 07/11/2023 | 07/13/2023 |

|   |  |  |
|---|--|--|
| <p>experiences <math>\geq 4</math> migraine days per month for at least 3 months".</p> <ol style="list-style-type: none"> <li>5. Initial Approval Criteria, I.A.3: Updated to remove prior age criteria "Age 18 years of age or older".</li> <li>6. Initial Approval Criteria, I.A.2: Rephrased prior trial and failure therapy criteria and included new therapy drug, Candesartan.</li> <li>7. Initial Approval Criteria, I.A.3: Updated to include new combination therapy criteria For members currently treated with Botox for migraine (must meet a, b, and c):             <ol style="list-style-type: none"> <li>a. Diagnosis of chronic migraine;</li> <li>b. Member has tried a minimum of 2 quarterly injections (6 months) of Botox;</li> <li>c. Member has experienced and maintained a positive response.</li> </ol> </li> <li>8. Initial Approval Criteria, I.A.4: Updated combination therapy criteria from Aimovig® is not prescribed concurrently with Botox® or other injectable CGRP inhibitors (e.g., Ajovy®, Emgality®) to Medication is not prescribed in combination with other CGRP inhibitors used for migraine prophylaxis*.<br/>             *Medication may be prescribed concurrently with other CGRP inhibitors used for acute migraine treatment.</li> <li>9. Initial Approval Criteria, I.A.6: Updated to remove prior dosing criteria "Dose does not exceed 140 mg (1 injection) once monthly".</li> <li>10. Initial Approval Criteria, I.A: Updated CGRP monotherapy initial approval duration from 3 to 12 months for Commercial and Medicaid.</li> <li>11. Initial Approval Criteria, I.A: Updated to include CGRP and Botox dual therapy initial approval duration for Commercial and Medicaid.</li> <li>12. Continued Therapy Approval Criteria, II.A.1 was updated from Member is currently receiving medication that has been authorized by RxAdvance or the member has previously met initial approval criteria listed in this policy to Member is currently receiving medication, excluding manufacturer samples.<br/><br/>             Continued Therapy Approval Criteria, II.A.2: Updated response to therapy criteria from Member has experienced and maintained positive response to therapy as evidenced by</li> </ol> |  |  |
|---|--|--|

|   |            |            |
|---|------------|------------|
| <p>a reduction in migraine days per month from baseline to Member has experienced and maintained positive response to therapy.</p> <p>14. Continued Therapy Approval Criteria, II.A.3: Updated to remove concurrently therapy criteria "Aimovig® is not prescribed concurrently with Botox or other injectable CGRP inhibitors (e.g., Ajovy, Emgality)".</p> <p>15. Continued Therapy Approval Criteria, II.A.3: Updated to include new criteria pertaining to indication Migraine Prophylaxis Members who are treated with Aimovig®, Ajovy®, or Qulipta™ AND Botox for chronic migraine prophylaxis, member has achieved &gt; 50% reduction in the frequency of days with headache or migraine.</p> <p>16. Continued Therapy Approval Criteria, II.A.4: Updated to remove prior dosing criteria "If request is for a dose increase, new dose does not exceed 140 mg (1 injection) once monthly".</p> <p>17. Continued Therapy Approval Criteria, II.A.4: Updated to include new combination therapy criteria "Medication is not prescribed in combination with other CGRP inhibitors used for migraine prophylaxis*.<br/>         *Medication may be prescribed concurrently with other CGRP inhibitors used for acute migraine".</p> <p>18. Continued Therapy Approval Criteria, II.A: Updated Approval duration from 6 to 12 months for Commercial and Medicaid.</p> <p>19. Appendix A: Updated to include abbreviation ICHD.</p> <p>20. Appendix D, General Information: Updated to include new information regarding clinical trial for drug fremanezumab-vfrm (Ajovy®).</p> <p>13. References were reviewed and updated</p> |            |            |
| Policy was reviewed.  | 11/27/2023 | 11/27/2023 |
| Policy was reviewed:<br>1. Updated trial and failure medications.<br>2. References were reviewed and updated.<br>3. Updated continuation criteria   | 11/01/2024 | 12/05/2024 |
| Policy was reviewed:<br>1. Updated initial language to reflect documentation for trial and failure is now required.   | 8/1/2025   | N/A        |
| Policy was reviewed:  | 11/1/2025  | 12/11/2025 |

|                              |  |  |
|------------------------------|--|--|
| 1. Ajovy removed from Policy |  |  |
|------------------------------|--|--|

